DK0951481T3 - Use of drugs with immunomodulatory effect in the treatment of amyotrophic lateral sclerosis - Google Patents

Use of drugs with immunomodulatory effect in the treatment of amyotrophic lateral sclerosis

Info

Publication number
DK0951481T3
DK0951481T3 DK97951843T DK97951843T DK0951481T3 DK 0951481 T3 DK0951481 T3 DK 0951481T3 DK 97951843 T DK97951843 T DK 97951843T DK 97951843 T DK97951843 T DK 97951843T DK 0951481 T3 DK0951481 T3 DK 0951481T3
Authority
DK
Denmark
Prior art keywords
receptors
immunoglobulins
gamma
bind
lateral sclerosis
Prior art date
Application number
DK97951843T
Other languages
Danish (da)
Inventor
Walter Dr Schubert
Original Assignee
Mpb Meltec Patent Und Beteilig
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19723690A external-priority patent/DE19723690A1/en
Application filed by Mpb Meltec Patent Und Beteilig filed Critical Mpb Meltec Patent Und Beteilig
Application granted granted Critical
Publication of DK0951481T3 publication Critical patent/DK0951481T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

It has been discovered that, in the case of amyotrophic lateral sclerosis, usually a lethal motoneuron disease, a large number of the immune system cells expressing receptors (Fc receptors) of immunoglobulins (IgC), preferably immunoglobulins of classes 1 and 3 (Fc gamma RIII receptors for IgG1 and IgG3) can be found in the blood stream. Selective destruction or functional obstruction of these cells can be achieved in order to treat amyotrophic lateral sclerosis (ALS) with the following substances, or their preparations ( in the form of intravenous applications or preparations), individually or in combination: a) antibodies, preferably monoclonal antibodies, which bind to Fc gamma RIII receptors, inactivate said receptors or individual species of this receptor family or cause the destruction of cellular forms containing said receptors, and/or are coupled to other cytotoxic substances, b) soluble Fc gamma receptors, preferably soluble Fc gamma RIII receptors which bind to immunoglobulins, preferably G immunoglobulins of under-class 1 (IgG1) and/or 3 (IgG3), c) the protein V which bind to immunoglobulin G, obtained from Gardnerella vaginalis, and d) antisense RNA molecules which bind specifically to mRNA sequences of Fc gamma receptors, preferably to those PF Fc gamma RIII receptors.
DK97951843T 1997-06-05 1997-12-10 Use of drugs with immunomodulatory effect in the treatment of amyotrophic lateral sclerosis DK0951481T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19723690A DE19723690A1 (en) 1996-06-05 1997-06-05 Use of Fc-gamma receptor antibodies
PCT/DE1997/002883 WO1999029731A1 (en) 1997-06-05 1997-12-10 Use of substances with immunomodulating activity for the treatment of amyotrophic lateral sclerosis

Publications (1)

Publication Number Publication Date
DK0951481T3 true DK0951481T3 (en) 2005-03-21

Family

ID=25962943

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97951843T DK0951481T3 (en) 1997-06-05 1997-12-10 Use of drugs with immunomodulatory effect in the treatment of amyotrophic lateral sclerosis

Country Status (7)

Country Link
EP (1) EP0951481B1 (en)
JP (1) JP2001511821A (en)
AT (1) ATE283290T1 (en)
DK (1) DK0951481T3 (en)
ES (1) ES2234038T3 (en)
PT (1) PT951481E (en)
WO (1) WO1999029731A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7030126B2 (en) 2001-11-16 2006-04-18 Als Therapy Development Foundation, Inc. Use of polyamine analogs for amyotrophic lateral sclerosis
EP3170899B1 (en) 2011-10-11 2020-06-24 The Brigham and Women's Hospital, Inc. Microrna mir-155 in neurodegenerative disorders
DE102016103562A1 (en) * 2015-09-17 2017-03-23 Topos Nomos Ltd. Pharmaceutical agents for use in the treatment of amyotrophic lateral sclerosis (ALS) and diagnostic procedures
DE102016106510A1 (en) * 2016-04-08 2017-10-12 ToposNomos Ltd. Method and device for extracorporeal removal of pathogenic and / or supernumerary components from a cell sample of a patient

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2655269B1 (en) * 1989-12-01 1994-02-11 Curie Universite Pierre Marie PROTEINS PREVENTING THE INTERACTION BETWEEN A FRAGMENT OF AN IMMUNOGLOBULIN AND ITS RECEPTOR AND USE IN THERAPEUTICS, ESPECIALLY IN THE TREATMENT OF CONDITIONS RELATED TO HIV VIRUSES.
FR2702481B1 (en) * 1993-03-09 1995-04-28 Roussel Uclaf New soluble human Fc-gamma III receptors, their preparation process, the pharmaceutical compositions containing them, their application as medicaments and their diagnostic application.
DE19723690A1 (en) * 1996-06-05 1998-03-26 Schubert Walter Dr Md Use of Fc-gamma receptor antibodies

Also Published As

Publication number Publication date
EP0951481B1 (en) 2004-11-24
ATE283290T1 (en) 2004-12-15
ES2234038T3 (en) 2005-06-16
WO1999029731A1 (en) 1999-06-17
JP2001511821A (en) 2001-08-14
EP0951481A1 (en) 1999-10-27
PT951481E (en) 2005-04-29

Similar Documents

Publication Publication Date Title
Ghetie et al. Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells
Billiau Gamma-interferon: the match that lights the fire?
Glennie et al. Clinical trials of antibody therapy
Lubeck et al. The interaction of murine IgG subclass proteins with human monocyte Fc receptors.
RU2220980C2 (en) Chimeric antibody that binds with human cd40 (variants), nucleic acid molecule (variants), expression vector (variants), humanized antibody (variants), pharmaceutical composition for treatment of disease mediated by t-cells (variants), method for treatment of patient with diseases mediated by t-cells (variants)
US4676980A (en) Target specific cross-linked heteroantibodies
Taylor Antibody therapy for rheumatoid arthritis
ATE454124T1 (en) RECOMBINANT ANTI-CD30 ANTIBODIES AND USES THEREOF
WO2006002177A3 (en) Interferon alpha receptor 1 antibodies and their uses
EP2418220A3 (en) Interferon alpha antibodies and their uses
SG165161A1 (en) Human monoclonal antibody against a costimulatory signal transduction molecule ailim and pharmaceutical use thereof
ATE477273T1 (en) HUMANIZED ANTIBODIES AGAINST GAMMA INTERFERON
YU34196A (en) Peptides and compounds that bind to a receptor
ATE348632T1 (en) PRION PROTEIN PEPTIDES AND THEIR USE
DK1331944T3 (en) Use of CD28-specific monoclonal antibodies to stimulate non-CD28 blood cells
MXPA03011499A (en) Fce fusion proteins for treatment of allergy and asthma.
Gorovits et al. Current considerations on characterization of immune response to multi-domain biotherapeutics
DK0845998T3 (en) Immunotherapy drugs containing antibodies that specifically recognize the MHCII antigen in a patient to be treated
ATE235551T1 (en) LIGAND (TIE LIGAND-4) FROM TIE-2 RECEPTOR AND ITS USES
DK0951481T3 (en) Use of drugs with immunomodulatory effect in the treatment of amyotrophic lateral sclerosis
CN1056084C (en) Immunotoxins directed against CD33 related surface antigens
DE69630682D1 (en) SYNTHETIC PEPTIDES AND MEDICINAL PRODUCTS FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATODES
Cardenas et al. Phosphorylation-dephosphorylation of the CD6 glycoprotein renders two isoforms of 130 and 105 kilodaltons. Effect of serum and protein kinase C activators.
Penichet et al. Antibody-IL-2 fusion proteins: a novel strategy for immune potentiation
CN101522714A (en) Ige-retargeting, function-altering molecules (ERFAM) for treatment of allergic diseases